Dihexa

Cognitive Health

Choose a treatment option

Oral Capsule

Easy, consistent dosing for systemic delivery

From $229/mo

Dihexa is an orally bioavailable, small-molecule peptide derivative specifically designed to cross the blood-brain barrier. Originally developed by researchers at Washington State University, it is a potent activator of the Hepatocyte Growth Factor (HGF) and its receptor, c-Met. Dihexa is being investigated for its potential to facilitate synaptogenesis (the formation of new functional synapses) and enhance cognitive function.

Check eligibility

Dihexa is not FDA-approved to diagnose, treat, cure, or prevent any disease or illness.

Why it works

Key benefits

Cognitive Support: Potential improvements in short-term and long-term memory.

Mental Clarity: Reduced "brain fog" and enhanced focus or task-switching abilities.

Neuro-Regeneration: Investigated for its ability to restore lost synaptic connections in neurodegenerative states.

Mood Support: Some patients report improved emotional resilience and mental energy.

Based on preclinical and pilot data

Mechanism

How it works

Dihexa acts as a high-affinity ligand for HGF, which is a powerful regulator of cell growth and survival. In the brain, the HGF/c-Met pathway plays a critical role in: Synaptogenesis: It promotes the formation of new connections between neurons, which is essential for learning and memory. Neuroprotection: It supports the survival of existing neurons under stress. Cognitive Enhancement: By increasing synaptic density, it may improve the speed and efficiency of signal transmission within the brain.

Frequently asked questions

FAQs

Cognitive effects from Dihexa can be subtle. While some patients report improved mental "sharpness" within 1–2 weeks, the structural process of synaptogenesis (building new connections) is cumulative. Most protocols suggest a 4–8 week duration to observe meaningful changes in cognitive performance.

Dihexa is generally well-tolerated, but because it is a potent neuro-active compound, some users may experience: Over-Stimulation: Feelings of jitteriness, anxiety, or irritability. Insomnia: Difficulty falling asleep if taken too late in the day. Headache: Mild, transient headaches during the first week of use. Gastrointestinal Distress: Rare reports of mild nausea with oral administration.

Research & Studies

Evidence at a Glance

1.
Benoist, C. C., et al. (2014). The orally bioavailable, blood-brain barrier-permeable small molecule Dihexa improves cognitive function.. Journal of Pharmacology and Experimental Therapeutics, 351(2), 390–402. https://doi.org/10.1124/jpet.114.218735.
2.
McCoy, A. T., et al. (2013). Evaluation of a novel angiotensin IV-based activity: Hepatocyte growth factor (HGF) activation and synaptogenesis.. Journal of Pharmacology and Experimental Therapeutics, 344(1), 141–154..
3.
Harding, G. W., et al. (2017). Dihexa, a small molecule angiotensin IV-analog, mimics the neuroprotective and synaptogenic effects of HGF.. Neuroscience Letters..

Interested in Dihexa?

Take a short assessment and a licensed provider will review if this treatment is right for you.

Check eligibility

Clinical Guidance Disclaimer

The information provided in this document is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. It should never replace sound clinical judgment or personalized advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read in these materials.

Liability & Indemnification

By utilizing this information, the user acknowledges and agrees that REBL and its affiliates, providers, and staff are not liable for any direct, indirect, or consequential damages resulting from the use or misuse of the information provided herein. Any reliance on the materials contained in this document is solely at the user's own risk.

Regulatory Status

Dihexa is an investigational compound. It is prepared by licensed 503A or 503B compounding pharmacies for research or off-label clinical use. It is not FDA-approved for the treatment of Alzheimer’s, dementia, or any other medical condition.

Proprietary Rights & Use Restrictions

This document and its contents are the proprietary property of REBL. Unauthorized use, duplication, reproduction, or distribution of these materials—in whole or in part—without express written consent is strictly prohibited.